000286103 001__ 286103
000286103 005__ 20240303005728.0
000286103 0247_ $$2doi$$a10.1080/21645515.2023.2289242
000286103 0247_ $$2pmid$$apmid:38078840
000286103 0247_ $$2ISSN$$a2164-5515
000286103 0247_ $$2ISSN$$a1554-8600
000286103 0247_ $$2ISSN$$a1554-8619
000286103 0247_ $$2ISSN$$a2164-554X
000286103 0247_ $$2altmetric$$aaltmetric:157826420
000286103 037__ $$aDKFZ-2023-02679
000286103 041__ $$aEnglish
000286103 082__ $$a610
000286103 1001_ $$aBhatla, Neerja$$b0
000286103 245__ $$aImpact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccine.
000286103 260__ $$aAustin, Tex.$$bLandes Bioscience$$c2023
000286103 3367_ $$2DRIVER$$aarticle
000286103 3367_ $$2DataCite$$aOutput Types/Journal article
000286103 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1702390513_9556
000286103 3367_ $$2BibTeX$$aARTICLE
000286103 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000286103 3367_ $$00$$2EndNote$$aJournal Article
000286103 520__ $$aLong-term follow-up of a cohort of unmarried girls who received one, two, or three doses of quadrivalent HPV vaccine, between 10 and 18 years of age, in an Indian multi-centric study allowed us to compare antibody responses between the younger and older age cohorts at 10-years post-vaccination, and study the impact of initiation of sexual activity and cervical HPV infections on antibody levels. Among the younger (10-14 years) recipients of a single dose, 97.7% and 98.2% had detectable binding antibody titers against HPV 16 and HPV 18 respectively at ten years post-vaccination. The proportions among those receiving a single dose at age 15-18 years were 92.3% and 94.2% against HPV 16 and HPV 18 respectively. Mean HPV 16 binding antibody titers were 2.1 folds (95%CI 1.4 to 3.3) higher in those vaccinated at ages 10-14 years, and 1.9 folds (95%CI 1.2 to 3.0) higher in those vaccinated at 15-18 years compared to mean titers seen in the unvaccinated women. Compared to previous timepoints of 36 or 48 months, binding antibodies against HPV 16 and neutralizing antibodies against both HPV 16 and HPV 18 were significantly higher at 10 years. This rise was more pronounced in participants vaccinated at 15-18 years. No association of marital status or cervical HPV infections was observed with the rise in titer. Durability of antibody response in single dose recipients correlated well with the high efficacy of a single dose against persistent HPV 16/18 infections irrespective of age at vaccination, as we reported earlier.
000286103 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000286103 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000286103 650_7 $$2Other$$aHPV
000286103 650_7 $$2Other$$aHuman papillomavirus
000286103 650_7 $$2Other$$aage-stratified
000286103 650_7 $$2Other$$abinding antibody
000286103 650_7 $$2Other$$aneutralizing antibody
000286103 650_7 $$2Other$$asingle dose
000286103 650_7 $$2Other$$avaccine
000286103 7001_ $$aMuwonge, Richard$$b1
000286103 7001_ $$aMalvi, Sylla G$$b2
000286103 7001_ $$aJoshi, Smita$$b3
000286103 7001_ $$aPoli, Usha Rani Reddy$$b4
000286103 7001_ $$aLucas, Eric$$b5
000286103 7001_ $$aEsmy, Pulikkottil O$$b6
000286103 7001_ $$aVerma, Yogesh$$b7
000286103 7001_ $$aShah, Anand$$b8
000286103 7001_ $$aZomawia, Eric$$b9
000286103 7001_ $$aPimple, Sharmila$$b10
000286103 7001_ $$aJayant, Kasturi$$b11
000286103 7001_ $$aHingmire, Sanjay$$b12
000286103 7001_ $$aChiwate, Aruna$$b13
000286103 7001_ $$aVashist, Shachi$$b14
000286103 7001_ $$aMishra, Gauravi$$b15
000286103 7001_ $$aJadhav, Radhika$$b16
000286103 7001_ $$aSiddiqi, Maqsood$$b17
000286103 7001_ $$aAnantharaman, Devasena$$b18
000286103 7001_ $$aPanicker, Gitika$$b19
000286103 7001_ $$0P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aButt, Julia$$b20$$udkfz
000286103 7001_ $$aSankaran, Subha$$b21
000286103 7001_ $$aKannan, Thiraviam Pillai Rameshwari Ammal$$b22
000286103 7001_ $$aVarghese, Rintu$$b23
000286103 7001_ $$aKartha, Purnima$$b24
000286103 7001_ $$aPillai, M Radhakrishna$$b25
000286103 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b26$$udkfz
000286103 7001_ $$0P:(DE-He78)41d8b55dd01aace350f81d031f9f707f$$aMüller, Martin$$b27
000286103 7001_ $$0P:(DE-He78)219d54a7bf634121fbf16bea82d434e1$$aSehr, Peter$$b28$$udkfz
000286103 7001_ $$aUnger, Elizabeth R$$b29
000286103 7001_ $$aSankaranarayanan, Rengaswamy$$b30
000286103 7001_ $$00000-0003-0124-4050$$aBasu, Partha$$b31
000286103 773__ $$0PERI:(DE-600)2664177-X$$a10.1080/21645515.2023.2289242$$gVol. 19, no. 3, p. 2289242$$n3$$p2289242$$tHuman vaccines & immunotherapeutics$$v19$$x2164-5515$$y2023
000286103 909CO $$ooai:inrepo02.dkfz.de:286103$$pVDB
000286103 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000286103 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b26$$kDKFZ
000286103 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)41d8b55dd01aace350f81d031f9f707f$$aDeutsches Krebsforschungszentrum$$b27$$kDKFZ
000286103 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)219d54a7bf634121fbf16bea82d434e1$$aDeutsches Krebsforschungszentrum$$b28$$kDKFZ
000286103 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000286103 9141_ $$y2023
000286103 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-28
000286103 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-28
000286103 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-28
000286103 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bHUM VACC IMMUNOTHER : 2022$$d2023-08-28
000286103 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-18T15:23:36Z
000286103 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-18T15:23:36Z
000286103 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-18T15:23:36Z
000286103 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-28
000286103 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-28
000286103 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-28
000286103 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-28
000286103 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-28
000286103 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-28
000286103 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-28
000286103 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-28
000286103 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-28
000286103 9201_ $$0I:(DE-He78)F020-20160331$$kF020$$lInfektionen und Krebs-Epidemiologie$$x0
000286103 9201_ $$0I:(DE-He78)W040-20160331$$kW040$$lGruppe Sehr EMBL$$x1
000286103 980__ $$ajournal
000286103 980__ $$aVDB
000286103 980__ $$aI:(DE-He78)F020-20160331
000286103 980__ $$aI:(DE-He78)W040-20160331
000286103 980__ $$aUNRESTRICTED